Epilepsy – Kepplah http://kepplah.com/ Sat, 25 Sep 2021 01:42:00 +0000 en-US hourly 1 https://wordpress.org/?v=5.8 https://kepplah.com/wp-content/uploads/2021/05/kepplah-150x150.png Epilepsy – Kepplah http://kepplah.com/ 32 32 Zogenix (ZGNX) drops 1.46% for September 24 https://kepplah.com/zogenix-zgnx-drops-1-46-for-september-24/ https://kepplah.com/zogenix-zgnx-drops-1-46-for-september-24/#respond Sat, 25 Sep 2021 01:42:00 +0000 https://kepplah.com/zogenix-zgnx-drops-1-46-for-september-24/

Zogenix Inc (NASDAQ: ZGNX), a company in Emeryville, Calif., Closed at $ 15.49 on Friday after losing $ 0.23 (1.46%) on 357,656 shares. The stock ranged from a high of $ 16.02 to a low of $ 15.48, while Zogenix’s market cap now stands at $ 865,855,032.

About Zogenix Inc

Zogenix is ​​a global biopharmaceutical company engaged in the development and commercialization of therapies with the potential to transform the lives of patients and their families living with rare diseases. The Company’s first rare disease treatment, FINTEPLA® (fenfluramine) oral solution has been approved by the US FDA and the European Medicines Agency and is under development in Japan for the treatment of seizures associated with Dravet syndrome. , severe and rare epilepsy for life. The company has two other late-stage development programs underway: one for FINTEPLA for the treatment of seizures associated with Lennox-Gastaut syndrome, another for rare epilepsy, and one for MT1621, an investigational therapy for the treatment. of a rare genetic condition called TK2 deficiency. . Zogenix is ​​also collaborating with Tevard Biosciences to identify and develop potential next-generation gene therapies for Dravet syndrome and other genetic epilepsies.

Visit the Zogenix Inc profile for more information.

The daily solution

The DoorDash food delivery service will now support delivery of beer, wine and spirits to 20 U.S. states, the District of Columbia, Canada and Australia, a move the company says could allow it to ” reach over 100 million customers.

Twitter (NYSE: TWTR) has disclosed a binding agreement to settle a consolidated class action lawsuit, under which the social media company will pay $ 809.5 million to resolve claims it provided misleading information to investors.

The Federal Reserve is reviewing the ethics policies that govern the financial holdings and activities of its senior officials following recent revelations that two regional Fed chairmen engaged in intensive year-round trade last.

About the Nasdaq Stock Market

The Nasdaq Stock Market is a global leader in trading data and services, as well as the listing of stocks and options. The Nasdaq is the world’s largest stock exchange for options volume and is home to the five largest US companies – Apple, Microsoft, Amazon, Alphabet and Facebook.

To get more information about Zogenix Inc and keep up with the latest company updates, you can visit the Company Profile page here: Zogenix Inc. Profile For more information on Financial Markets, no. be sure to visit Equities News. Also, don’t forget to sign up for the Daily Fix to get the best stories delivered to your inbox 5 days a week.

Sources: The chart is provided by TradingView on the basis of prices delayed by 15 minutes. All other data is provided by IEX Cloud as of 8:05 p.m. ET on the day of publication.

The views and opinions expressed in this article are those of the authors and do not represent the views of equities.com. Readers should not take the author’s statements as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please visit: http://www.equities.com/disclaimer

President Biden welcomes leaders of India, Japan and Australia to first “Quad” summit on Friday

Some Chinese Banks Stop Offering New Loans To Real Estate Developers Amid Evergrande Fear

Iowa Senator Chuck Grassley is running for eighth term

Special House committee assigns four Trump allies in U.S. Capitol riots investigation

CDC approves COVID-19 vaccine booster shots for millions of elderly and vulnerable people

Semiconductor shortage to cost global auto industry $ 210 billion in revenue in 2021

US Olympians Must Be Vaccinated Against COVID-19 For Beijing Winter Games

FAA urges airlines to take stronger action with unruly and disruptive passengers

Source link

https://kepplah.com/zogenix-zgnx-drops-1-46-for-september-24/feed/ 0
Late actor Cameron Boyce honored ahead of ‘Runt’ Los Angeles premiere https://kepplah.com/late-actor-cameron-boyce-honored-ahead-of-runt-los-angeles-premiere/ https://kepplah.com/late-actor-cameron-boyce-honored-ahead-of-runt-los-angeles-premiere/#respond Fri, 24 Sep 2021 16:22:00 +0000 https://kepplah.com/late-actor-cameron-boyce-honored-ahead-of-runt-los-angeles-premiere/

Cameron Boyce has been methodical in preparing “Runt”, the independent drama that follows his character Cal, a high school student neglected by the adults in his life who becomes a target of bullying, which leads him to resort to to violence. “Runt” became the actor’s last film before his death from an epileptic seizure on July 6, 2019.

Aramis Knight, who plays Vic in the film, paid tribute to Boyce ahead of the Los Angeles premiere at the TCL Chinese Theater on September 22. “I think he’s really special in this movie,” Knight said. “I hope they see a side of Cameron they haven’t seen before.”

Best friend and co-star of “Jessie” on the Disney Channel, Karan Brar said he knew how important the film was to Boyce. “I’m really proud of him as a best friend.”

Sarah Jefferey, who starred alongside Boyce in the “Descendants” franchise, said Boyce was eagerly waiting for audiences to see the film. “I remember hearing him talk about it when we were filming ‘Descendants’. He was really excited for it, which makes it really moving.

Libby and Victor Boyce discussed the premiere of “Runt” and seeing their son back on the big screen. “It’s very bittersweet,” said Victor. “We are very happy that it came out and we are proud of our son’s work.” Libby Boyce added: “We know how much he put in and it shows and so we are very proud of that.”

After the star’s death, the Cameron Boyce Foundation was established, honoring his legacy by reducing gun violence and curing epilepsy – issues Boyce was passionate about.

“We have been surprised by the growth we have seen from the start,” said Victor. “In two years, we’ve already funded a few major epilepsy research grants and we’ve raised over $ 1 million. We partner with other organizations that Cameron loved and supported.

“After Cameron passed away, it was very tragic for everyone and the whole community came together and wanted to support each other the best they could,” said Brar. “For the moment, the objective is to fight against epilepsy – Sudep in particular, and to find the cure. I think the conversation about epilepsy doesn’t have as many nuances and we hope to broaden that conversation. “

“Being part of the foundation, we are very grateful for the support of ‘Runt’ for us, but tonight it’s really about celebrating one of his latest works,” said actress Sophie Reynolds, who does part of the foundation’s advisory board.

“Runt” was Boyce’s heaviest role, pulling him away from comedy in the Disney Channel franchise. “People thought of him as a Disney character and he was very good at Disney,” said Libby Boyce. “But he was also in the acting business, and it was really important for him to get that part and show his acting skills – he wasn’t just a comedy actor for Disney, it was a truly incredible actor. “

“Runt” hits theaters on October 1.

Source link

https://kepplah.com/late-actor-cameron-boyce-honored-ahead-of-runt-los-angeles-premiere/feed/ 0
An accountant warned by bosses after an epileptic seizure https://kepplah.com/an-accountant-warned-by-bosses-after-an-epileptic-seizure/ https://kepplah.com/an-accountant-warned-by-bosses-after-an-epileptic-seizure/#respond Thu, 23 Sep 2021 14:59:00 +0000 https://kepplah.com/an-accountant-warned-by-bosses-after-an-epileptic-seizure/
Iman Barakat worked for the accountants of Alvis & Company in Hampton, London (Photo: Google Maps)

A trainee accountant who suffered from epilepsy was told to “show gratitude” to those who covered her work while she was on sick leave.

Iman Barakat, who worked for Alvis & Company’s accountants in Hampton, London, received an official warning from bosses after having a seizure and was rushed to hospital.

Her premium was also reduced from £ 7,000 to £ 750 due to the period during which she had stopped working.

She has now won complaints of victimization, disability-related harassment, unfavorable treatment, unfair dismissal and unfair dismissal in labor court.

Ms Barakat said her managers had shown no empathy and that some even refused to believe that she really had epilepsy, despite having a seizure in front of them.

She is now awaiting compensation after the court ruled that her bosses’ actions “were intended to violate Ms. Barakat’s dignity and create an intimidating, hostile, degrading, humiliating or offensive environment for her.”

Ms. Barakat started working for the company as a trainee accountant in 2016, and suffered from epilepsy and chronic migraines since childhood.

Her seizures started again while working for the accountants, so she told bosses about her illnesses six months after she started.

Accountant received official warning from bosses after crisis and rushed to hospital

Caption: Accountant receives official warning from bosses after she had a seizure and was rushed to hospital Images: Getty / Google Maps

In October 2018, Ms. Barakat had a seizure at home one day without realizing it and burned her leg with her hair straightener.

Later that same day, she had a 10-minute epileptic seizure at work which some of her co-workers witnessed.

She was then absent from work for a month after the burn became infected, and she said when she returned she felt guilty.

Bosses James Bolger and Brian Mason said her colleagues complained that she was receiving “special treatment”, told her she was “ungrateful” and that she should show “empathy” for those who covered her.

In December 2018 and January 2019, she had epileptic seizures and was unable to make herself sick as she was rushed to hospital.

She said her bosses didn’t give her a chance to explain why she couldn’t call and that she received official written warnings each time.

In an email to the company describing her concerns about the treatment of her bosses, Ms Barakat said: “I was on leave due to a third degree burn that was permanently disfiguring me and [they] never failed to make me forget the impact she had on “the team”.

‘Corn [they] had no empathy or interest in me and the attitude that I am somehow in control of my condition.

‘[They] asked if i was epileptic, but i had a seizure before [them] – the resentment and disbelief of my condition is shocking and insulting.

“As an employer, you have a duty to protect me from such harassment and you haven’t.

“You participated and allowed people to talk about me while you yourself relayed it to me.

‘[They] implied that I delayed a medical report due to “something out there that I didn’t want you to know” that suggested I was lying about something to do with my condition. ‘

After her complaints, the bosses told her they would demand a medical report on her condition, then fired her.

Their motives were that Ms Barakat had not “accepted responsibility for certain matters” and had “attempted to lay the blame on others”.

But the court ruled that she was in fact fired over her discrimination complaints, sickness absences and concerns that her colleagues were talking about her.

Judge Antony Hyams-Parish said: “The court found that [the employers] Constantly criticizing Ms. Barakat and asking her to empathize with her colleagues was undesirable behavior.

“This was intended to undermine Ms. Barakat’s dignity and create an intimidating, hostile, degrading, humiliating or offensive environment for her.”

She also won a claim that her bosses failed to make reasonable adjustments for her illness because she was not allowed to work from home.

Contact our press team by emailing us at webnews@metro.co.uk.

For more stories like this, see our news page.

Source link

https://kepplah.com/an-accountant-warned-by-bosses-after-an-epileptic-seizure/feed/ 0
Epilepsy Market Size Competitive Strategies and Forecasts https://kepplah.com/epilepsy-market-size-competitive-strategies-and-forecasts/ https://kepplah.com/epilepsy-market-size-competitive-strategies-and-forecasts/#respond Thu, 23 Sep 2021 07:54:52 +0000 https://kepplah.com/epilepsy-market-size-competitive-strategies-and-forecasts/

Market research

Epilepsy Market Overview
Epilepsy is a disorder of the central nervous (neurological) system in which brain activity becomes abnormal, causing seizures or periods of unusual behavior, sensations, and sometimes loss of consciousness.
The epilepsy market is dynamic due to increased government funding for the development of new effective drugs for the treatment of seizures. In addition, various awareness programs conducted by organizations will additionally provide lucrative opportunities in the market during the review period.
The ‘Epilepsy Market Analysis to 2028’ is a specialized and in-depth study of the healthcare industry with special emphasis on the analysis of global market trends. The report aims to provide an overview of the epilepsy market with detailed market segmentation by condition, diagnosis and treatment and end user. The epilepsy market is expected to witness strong growth during the forecast period. The report provides key statistics on the market status of the major players in the epilepsy market and presents key trends and opportunities in the market.

Epilepsy market sample request to find out which pharmaceutical and biotech company should be at the forefront in the years to come @

Some of the prominent / emerging players in the epilepsy market:
– LivaNova SA
– GlaxoSmithKline PLC
– Eisai Co. Ltd.
– Pfizer Inc.
– Medtronic PLC
– GW Pharmaceuticals PLC
– Novartis SA
– Johnson & Johnson Services inc.
– Abbott Laboratories
– Becton Dickinson and company

Key Questions Regarding the Current Epilepsy Market Landscape
1. What are the current options for the epilepsy market?
2. How many companies are developing for the epilepsy market?
3. What are the key collaborations (Industry-Industry, Industry-University), mergers & acquisitions, and significant licensing activities that will impact the Epilepsy market?
4. What are the dormant and abandoned products and the reasons for them?
5. What is the unmet need in the current epilepsy market?
6. What are the new therapies, targets, mechanisms of action and technologies currently being developed to overcome the limitations of existing epilepsy?
7. What are the critical designations that have been granted for the epilepsy market?

Segmental Overview of the Epilepsy Market:
The epilepsy market is segmented on the basis of condition, diagnosis and treatment, and end user. On the basis of the state, the market is segmented into Drug Resistant Epilepsy / Untreatable Epilepsy and Others. On the basis of diagnosis and treatment, the market is segmented into imaging devices, blood tests, anti-epileptic drugs, and others. On the basis of end user, the market is segmented into hospitals, clinics, outpatient surgical centers, diagnostic centers, and others.
The report specifically highlights the Epilepsy market share, company profiles, regional outlook, product portfolio, a record of recent developments, strategic analysis, major market players, sales, distribution chain, manufacturing, production, new market entrants as well as market players, advertising, brand value, popular products, demand and supply and other important market related factors to help new entrants to better understand the market scenario.

To understand the global epilepsy market dynamics around the world mainly, the global market is analyzed in the major regions of the world: North America (United States, Canada and Mexico), Europe (Germany, France, United Kingdom , Russia and Italy), Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia), South America (Brazil, Argentina), Middle East and Africa (Saudi Arabia, United Arab Emirates, Egypt and South Africa)
Our sample report contains a brief introduction of the research report, table of contents, list of tables and figures, competitive landscape and geographic segmentation, innovation and future developments based on the methodology of research.

Reasons to buy:
1. The nature of epilepsy business opportunities has become increasingly complex with the industry changing at a faster rate, making it increasingly difficult to do without adequate market information. and businesses.
2. Gain complete understanding of global epilepsy industry through comprehensive analysis
3. Evaluate the pros and cons of investing / operating in epilepsy markets at national level using reliable forecasting model results
4. Identify potential investment / contract / expansion opportunities
5. Drive your strategies in the right direction by understanding the impact of the latest trends and market forecasts on your Epilepsy business.
6. Beat your competition with information on their operations, strategies and new projects
7. Recent insights into the epilepsy market will help users operating in the market to initiate transformational growth

Interested in purchasing this report? Click here @

Contact us
Contact Person: Sameer Joshi
Phone: + 1-646-491-9876
Email: sales@theinsightpartners.com

About Us
The Insight Partners is a one-stop-shop for actionable information in industrial research. We help our clients find solutions to their research needs through our syndicated research and advisory services. We specialize in industries such as semiconductors and electronics, aerospace and defense, automotive and transportation, biotechnology, healthcare IT, manufacturing and construction, medical devices , technology, media and telecommunications, food and beverage, consumer goods and chemicals and materials.

This version was posted on openPR.

Source link

https://kepplah.com/epilepsy-market-size-competitive-strategies-and-forecasts/feed/ 0
Bright Minds Biosciences Advances Lead Serotonergic Drug Candidate in Toxicology Studies, Targeting Human Trials in 2022 https://kepplah.com/bright-minds-biosciences-advances-lead-serotonergic-drug-candidate-in-toxicology-studies-targeting-human-trials-in-2022/ https://kepplah.com/bright-minds-biosciences-advances-lead-serotonergic-drug-candidate-in-toxicology-studies-targeting-human-trials-in-2022/#respond Wed, 22 Sep 2021 19:24:00 +0000 https://kepplah.com/bright-minds-biosciences-advances-lead-serotonergic-drug-candidate-in-toxicology-studies-targeting-human-trials-in-2022/

Bright Minds Biosciences (CSE: DRUG) today shared scientific updates regarding its serotonergic drug pipeline. This includes the announcement of the advancement of the company’s proprietary agonist, BMB-101, to the experimental stage of a new drug allowing safety and toxicology studies for its potential treatment of Dravet syndrome.

The biotech company selects BMB-101 as a flagship drug candidate for its program to target the nervous system receptor 5-HT2C, which is one of several serotonin binding sites. The proprietary compound has been shown to be effective in the treatment of a rare form of epilepsy called Dravet syndrome in rodent models. Therefore, the company also shared the update that it identifies the syndrome as the primary indication for BMB-101.

“Over the past few months, we have significantly improved BMB’s competitive position with our therapeutic classes, as well as our broader capital markets strategy,” said Ian McDonald, CEO of Bright Minds.

The company indicated that the activation of toxicology studies for the compound 5-HT2C is a precursor for the conduct of human trials. Phase 1 and Phase 2 trials are scheduled for the first half and second half of 2022, respectively.

In addition, based on its clinical studies for BMB-101 which established efficacy results in rat models, the company also identified other indications that could potentially be treated with the compound, including the disorder opioid use and binge eating disorder.

Our compounds are in the advanced preclinical stage and have demonstrated compelling data in well accepted animal models for Dravet syndrome, a rare form of childhood epilepsy, opioid withdrawal, binge eating and Alzheimer’s disease psychosis. . Looking ahead, we plan to launch our first human trial of BMB-101 early next year to investigate the possible use of this new patented drug to treat Dravet syndrome.

Ian McDonald, CEO of Bright Minds

In the future, the company’s program for the treatment of depression and other neuropsychiatric disorders is currently testing several potential 5-HT2A drug candidates. On the other hand, its new compound for 5-HT2A + 5-HT2C receptors is in early preclinical development for several chronic pain disorders or neuropathic pain syndromes.

The biotech company also said it had recently established collaborative agreements with the National Institutes of Health for its preclinical screening program for chronic pain indications and the epilepsy treatment program.

The company was given a price target of $ 11.50 by Eight Capital earlier this month, a move based on the outlook for flagship drug candidate BMB-101.

Bright Minds Biosciences last traded at $ 7.64 on the CSE.

FULL DISCLOSURE: Bright Minds Biosciences is a client of Canacom Group, the parent company of The Deep Dive. The company was paid to cover Bright Minds Biosciences on The Deep Dive, with The Deep Dive having full editorial control. Not a buy or sell recommendation. Always do additional research and consult a professional before purchasing a title.

Source link

https://kepplah.com/bright-minds-biosciences-advances-lead-serotonergic-drug-candidate-in-toxicology-studies-targeting-human-trials-in-2022/feed/ 0
“We have seen it deteriorate every day. It was torture. https://kepplah.com/we-have-seen-it-deteriorate-every-day-it-was-torture/ https://kepplah.com/we-have-seen-it-deteriorate-every-day-it-was-torture/#respond Wed, 22 Sep 2021 06:49:08 +0000 https://kepplah.com/we-have-seen-it-deteriorate-every-day-it-was-torture/

For more parenting stories and (non-judgmental) advice check out Grazia’s parenting community on Instagram @TheJuggleUK

When my third daughter arrived, my older children were seven and four years old, respectively. Motherhood should have been a snap now – the older ones were in school and I knew what I was doing with a baby. This was my last, and I had the time and space to enjoy it before I got back to work. The first two years were indeed happy. Our daughter, Lola, was adored by her older siblings and, of course, her parents and extended family. She was a joy – brilliant, full of cheeky character. I then started my own financial consulting business so that I could work flexibly with the children and it was going well.

But then our world was fractured when, out of the blue, at just two years old, Lola developed a rare and serious seizure disorder, the cause of which has never been found. I knew very little about epilepsy until Lola started to have it, nor any of my friends or family – certainly no one had seen anything like Lola. She suffered an average of seventy seizures per day. She became extremely hyperactive while at the same time she started to lose all of her skills – her speech, her playing ability, her toilet training, everything. She was a danger to herself, not only because she didn’t understand dangerous situations, but also because she was physically strong and active – a very difficult combination. For example, she was trying to climb out the window on the roof. Not only that, but she had so many seizures that she could bang her head against any walls, floor, or furniture at any time.

Lola didn’t sleep well either. She would be awake and hyperactive for hours every night. My husband and I took turns on the night shift, but we were on our knees, trying to juggle jobs, our other kids, and keep each other together. It put a strain on our relationship. And it was incredibly lonely because no one, not the medical professionals or friends, no matter how kind and well-meaning they were, had a clue what we were going through. The worst part was not seeing the end of the situation, or a way to improve. We saw it deteriorate little by little every day, and there was nothing we could do to stop it. It was torture.

It wasn’t until I reached out and let others help, that things started to improve.

Eventually when I was at my lowest I finally asked close friends and family for help and a sympathetic ear it helped me tremendously. Allowing others to take some of the pressure really saved me.

When Lola was three and a half years old, doctors tried a new drug called Levetiracetam and – miraculously – it finally worked. Lola had had her last seizure, but at that point her mental age was only ten months old. We made it through those difficult years with the support of a children’s hospice where she went one night a week so that we could sleep. We also had a wonderful and kind neighbor who looked after Lola a few times a week, which gave me precious hours to spend with my other children and myself. And I will always be grateful to the family and friends who have been there for us throughout the process.

Lola is now a teenager, who has far exceeded all doctors’ expectations. She has academic difficulties, but she is very athletic, bright and funny. She has many friends and, with support, attends a regular school.

When I was in the midst of this nightmare, I did what I could to survive each day, trying to fend for myself. But I couldn’t. It wasn’t until I reached out and let others help me that things started to improve. These years have been so hard, but they have been made bearable by the kindness of others, and it is something I will never forget.

The Hidden Child by Louise Fein, published by Head of Zeus, now hardcover (£ 18.99)

Source link

https://kepplah.com/we-have-seen-it-deteriorate-every-day-it-was-torture/feed/ 0
Latest death in Rikers: Isaabdul Karim, who almost qualified for release https://kepplah.com/latest-death-in-rikers-isaabdul-karim-who-almost-qualified-for-release/ https://kepplah.com/latest-death-in-rikers-isaabdul-karim-who-almost-qualified-for-release/#respond Tue, 21 Sep 2021 17:14:08 +0000 https://kepplah.com/latest-death-in-rikers-isaabdul-karim-who-almost-qualified-for-release/

Mr Karim was held in an admission cell for 10 days, his lawyers and Ms Huff Bullock said. He had limited access to food and was denied medication, they said. Prison and correctional health officials did not immediately respond to questions about the allegations.

“’They don’t feed us,’” Ms. Huff Bullock recalled on a phone call. “I don’t know what’s going on. They treat us like animals; worse than animals.

During her preliminary hearing into the parole violation on August 31, Ms McEvilley said her lawyers requested early release, citing deteriorating health. The hearing was cut short, she said, after Mr Karim suffered an asthma attack. He was due to return for arraignment on September 27.

But advocates for those in jail said Mr Karim should never have been detained.

“He should have been in the community with his family, friends and network, not in a prison in the grip of an ongoing humanitarian crisis,” said Tina Luongo, the lawyer in charge of the criminal defense practice of the Legal Aid Society. “The technical violations – including the use of marijuana and failure to report, the non-criminal charges that led to Mr. Karim’s pre-trial detention – should not amount to a death sentence. “

In the days leading up to his death, Mr Karim had slipped and fell in the shower and then complained of chest pain, Ms Huff Bullock said, according to other inmates. She said the doctors planned to do an x-ray, but never did. Mr Karim had complained on Sunday that his chest pain had worsened, Ms Huff Bullock said. He died in a North Infirmary Command medical clinic at 7:25 p.m.

“They were really playing Russian roulette with him,” Ms. Huff Bullock said in tears. “They allowed him to die.

She blamed Mayor Bill de Blasio and prison officials for not doing more to save Mr Karim and lambasted correctional officers, some of whom were accused of calling in sick to avoid having to work. Almost a third of the prison system staff have been ill or unable to work with inmates.

Source link

https://kepplah.com/latest-death-in-rikers-isaabdul-karim-who-almost-qualified-for-release/feed/ 0
Swedish family travels to Utah for innovative brain implant https://kepplah.com/swedish-family-travels-to-utah-for-innovative-brain-implant/ https://kepplah.com/swedish-family-travels-to-utah-for-innovative-brain-implant/#respond Tue, 21 Sep 2021 03:13:38 +0000 https://kepplah.com/swedish-family-travels-to-utah-for-innovative-brain-implant/

SALT LAKE CITY, Utah (ABC4) – An 11-year-old girl travels to Utah to become the first European child to receive innovative brain implant treatment for epilepsy.

The young girl, Edith, was deprived of her childhood due to a lifelong struggle with severe seizures. Her family say Edith has been ill for over four years now, and almost died at one point due to an uncontrolled seizure.

Her family first noticed the disease when Edith was 7 years old. She came home from school one day feeling very ill with a high fever, excessive loss of energy and flu-like symptoms. The situation worsened when she was found shaking uncontrollably with blood in her mouth, unable to wake up.

Edith spent a month in a Swedish intensive care unit completely sedated, with doctors unable to control her tremors and raging fever. Her family believed she would not make it out alive. Fortunately, Edith was able to wake up, but her life has been radically changed since this first epileptic episode.

Her family were desperate to find a solution and discovered a tunnel of light while listening to a podcast.
They overheard a conversation about an innovative pacemaker with Dr. Robert Bollo, surgical director of the Pediatric Epilepsy Program at Primary Children’s Hospital in Salt Lake City.

The invention, called NeuroPace RNS, is an epilepsy device that offers personalized treatment by responding to abnormal brain activity. The device is FDA approved, but was not available in Sweden, so Edith’s family flew to Utah, hoping the innovative implant device could finally bring their lives back to life. girl.

“She doesn’t really have a life right now and that’s what we’re fighting to give her. But whatever crises do to him is even worse. She can’t ride a bike, play with her friends, as soon as we try to do something she has horrible seizures and they knock her out and affect her cognition, mood and well being … so she doesn’t never smells good, ”Carl says Molstad Edith’s father.

Edith was able to surgically implant the device in June and doctors are still monitoring her reaction to the procedure. She is scheduled for an update visit in December. The pacemaker’s journey is not instantaneous, they say, and only time will tell if Edith can finally stop struggling and enjoy her childhood again.

About 30 NeuroPace RNS devices have been implanted in Utah, with the battery due to be replaced after eight years. Edith’s family doesn’t know what the future holds or if Edith will need this device for the rest of her life, but they hope surgery will be the answer to all their prayers.

Source link

https://kepplah.com/swedish-family-travels-to-utah-for-innovative-brain-implant/feed/ 0
Pediatric Absence Epilepsy Treatment Market Size, Growth, and Key Players – Pfizer Teva Pharmaceutical Industries Ltd., Cavion AbbVie Insys Therapeutics, and GlaxoSmithKline Plc. https://kepplah.com/pediatric-absence-epilepsy-treatment-market-size-growth-and-key-players-pfizer-teva-pharmaceutical-industries-ltd-cavion-abbvie-insys-therapeutics-and-glaxosmithkline-plc/ https://kepplah.com/pediatric-absence-epilepsy-treatment-market-size-growth-and-key-players-pfizer-teva-pharmaceutical-industries-ltd-cavion-abbvie-insys-therapeutics-and-glaxosmithkline-plc/#respond Mon, 20 Sep 2021 15:24:19 +0000 https://kepplah.com/pediatric-absence-epilepsy-treatment-market-size-growth-and-key-players-pfizer-teva-pharmaceutical-industries-ltd-cavion-abbvie-insys-therapeutics-and-glaxosmithkline-plc/

New Jersey, United States, – The Child Absence Epilepsy Treatment Market The research report is an in-depth study that provides industry-wide insights into existing and emerging growth patterns, end-user analysis, and other key data that has been tested and validated by experts. and industry professionals. The report studies the market for importance, share, size, demand and supply, models, competitive landscape, industry chain analysis, and other important factors. The report also provides a detailed overview of the driving forces of the industry, along with the micro and macroeconomic factors that are likely to affect its development.

The Absence Epilepsy Treatment in Children market research report assesses the global Pediatric Absence Epilepsy Treatment industry market and includes forecast of sales and capacity for the planned period 2021-2028. The factors driving the growth of the industry are highlighted in the report. The report divides the childhood absence epilepsy treatment market into broad categories such as forms, applications, end user, technology, and others for better understanding. These segments are carefully examined to provide a more detailed perspective on the global and regional markets. The report also examines key industry players including their product portfolios, company overviews, strategic growth strategies, revenue generation, market share and size, geographic presence and size. of the market. development and manufacturing capabilities.

The market size of absent epilepsy treatment in children is increasing at a faster rate with substantial growth rates in recent years and the market is estimated to witness significant growth during the period. planned, i.e. from 2021 to 2028.

The report has conducted extensive research on the market segments and sub-segments and clarified which market segment will dominate the market during the forecast period. To help clients to make informed decisions on company investment plans and strategies in the Pediatric Absence Epilepsy Treatment market, the report involves in-depth information on regional market performance and competitive analysis.

The report covers an in-depth analysis of the major market players in the market, along with their business overview, expansion plans, and strategies. The major players studied in the report include:

Pfizer Teva Pharmaceutical Industries Ltd., Cavion AbbVie Insys Therapeutics and GlaxoSmithKline Plc.

Segmentation of the absent epilepsy treatment market in children

Child Absence Epilepsy Treatment Market, By Drug

• Valproate
• Lamotrigine
• Ethosuximide
• Phase 2 drugs

Child Absence Epilepsy Treatment Market, By Disease Type

• Atypical absence crises
• Typical absence seizures

Scope of Pediatric Absence Epilepsy Treatment Market Report

Report attribute Details
Market size available for years 2021 – 2028
Reference year considered 2021
Historical data 2015 – 2020
Forecast period 2021 – 2028
Quantitative units Revenue in millions of USD and CAGR from 2021 to 2028
Covered segments Types, applications, end users, etc.
Cover of the report Revenue forecast, company ranking, competitive landscape, growth factors and trends
Regional scope North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Scope of customization Free customization of the report (equivalent to up to 8 working days for analysts) with purchase. Add or change the scope of country, region and segment.
Price and purchase options Take advantage of personalized shopping options to meet your exact research needs. Explore purchasing options

Geographic segment covered in the report:

The Absence Epilepsy Treatment in Children report provides information about the market area which is itself further subdivided into sub-regions and countries / regions. In addition to the market share in each country and sub-region, this chapter of this report also contains information on profit opportunities. This chapter of the report mentions the market share and growth rate of each region, country and sub-region during the estimated period.

  • The Middle East and Africa (GCC countries and Egypt)
  • North America (United States, Mexico and Canada)
  • South America (Brazil etc …)
  • Europe (Turkey, Germany, Russia UK, Italy, France, etc.)
  • Asia Pacific (Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia and Australia)

Key questions answered in the report:

  • Who are the major global players in this Childhood Absence Epilepsy Treatment market?
  • What is their company profile, their product information, their contact details?
  • What was the global market status of the market?
  • What was the capacity, production value, cost and profit of the market?
  • What are the projections of the global industry taking into account the capacity, output and production value?
  • What will the cost and profit estimate be?
  • What will be the market share, supply and consumption?
  • What is the market chain analysis by upstream commodity and downstream industry?
  • What are the market dynamics of the market?
  • What are the challenges and opportunities?
  • What should be the entry strategies, the countermeasures to the economic impact, the marketing channels for the industry?

Visualize the Child Absence Epilepsy Treatment Market Using Verified Market Intelligence: –

Verified Market Intelligence is our BI platform for narrative storytelling for this market. VMI offers in-depth forecasting trends and accurate insights into over 20,000 emerging and niche markets, helping you make critical revenue-impacting decisions for a bright future.

VMI provides a holistic overview and global competitive landscape with regard to region, country and segment as well as the major players in your market. Present your market report and findings with a built-in presentation function, saving over 70% of your time and resources for investor arguments, sales and marketing, R&D and product development. VMI enables data delivery in interactive Excel and PDF formats with over 15+ key market indicators for your market.

About Us: Verified Market Research®

Verified Market Research® is a leading global research and consulting company providing advanced analytical research solutions, personalized advice and in-depth data analysis for over 10 years to individuals and businesses seeking precise research, reliable and up to date. technical data and advice. We provide insight into strategic and growth analytics, the data needed to meet business goals and help make critical revenue decisions.

Our research studies help our clients make superior data-driven decisions, understand market forecasts, capitalize on future opportunities, and optimize efficiency by working as a partner to deliver accurate and valuable information. The industries we cover cover a broad spectrum including technology, chemicals, manufacturing, energy, food and beverage, automotive, robotics, packaging, construction, mining and manufacturing. gas. Etc.

At Verified Market Research, we help understand holistic factors indicating the market and most current and future market trends. Our analysts, with their deep expertise in data collection and governance, use industry techniques to gather and examine data at all stages. They are trained to combine modern data collection techniques, superior research methodology, subject matter expertise, and years of collective experience to produce informative and accurate research.

After serving over 5,000 clients, we have provided reliable market research services to over 100 Global Fortune 500 companies such as Amazon, Dell, IBM, Shell, Exxon Mobil, General Electric, Siemens, Microsoft, Sony and Hitachi. We have co-consulted with some of the world’s largest consulting firms such as McKinsey & Company, Boston Consulting Group, Bain and Company for personalized research and consulting projects for businesses around the world.

Contact us:

Mr. Edwyne Fernandes

Verified Market Research®

United States: +1 (650) -781-480
UK: +44 (753) -715-0008
APAC: +61 (488) -85-9400
US Toll Free: +1 (800) -782-1768

E-mail: sales@verifiedmarketresearch.com

Website:- https://www.verifiedmarketresearch.com/

Source link

https://kepplah.com/pediatric-absence-epilepsy-treatment-market-size-growth-and-key-players-pfizer-teva-pharmaceutical-industries-ltd-cavion-abbvie-insys-therapeutics-and-glaxosmithkline-plc/feed/ 0
Study Links Commonly Prescribed Antiepileptic Drugs to Increased Fracture Risk in Children with Epilepsy https://kepplah.com/study-links-commonly-prescribed-antiepileptic-drugs-to-increased-fracture-risk-in-children-with-epilepsy/ https://kepplah.com/study-links-commonly-prescribed-antiepileptic-drugs-to-increased-fracture-risk-in-children-with-epilepsy/#respond Mon, 20 Sep 2021 05:02:35 +0000 https://kepplah.com/study-links-commonly-prescribed-antiepileptic-drugs-to-increased-fracture-risk-in-children-with-epilepsy/

Among the many medical conditions that can hamper or hinder a happy childhood is the prevalence of epilepsy. However, it can be managed with prompt medical intervention and lead to a relatively normal childhood. Now, a new study has found that a commonly prescribed anti-seizure drug may increase the risk of fractures in children with epilepsy.

According to a multi-institutional team of researchers, oxcarbazepine, a common anti-seizure drug, may increase the risk of fractures in children with epilepsy. The authors analyzed the effects of two of the most widely prescribed anti-epileptic drugs, levetiracetam and oxcarbazepine, on bone fragility in children aged four to 13 years. The results of the study have been published in the journal. Epilepsy.

“Prior to this study, little research had been done on the impact of these two commonly prescribed drugs on bone fragility. These findings provide essential insight into the impact of two commonly prescribed drugs on children and adolescents over a period of time. critical of bone development, ”Dr. Daniel Whitney, lead author of the study, said in a statement.

Most commonly prescribed anti-epileptic drugs

Tablets (representative image)Pixabay

Several factors during the pre to mid-puberty phase combine in the development of bone strength, which peaks in adulthood. This includes aspects such as bone biology, bone structure, and genetics, among others. Any disorder during these crucial developmental years can coalesce to have lasting effects on the musculoskeletal system.

Epilepsy is a chronic disease of the brain that affects people of all ages. According to the WHO, more than 50 million people live with this disease worldwide. It causes seizures and is one of the most common nervous system disorders in the world. A seizure is experienced when one or more parts of the brain have bursts of abnormal electrical signals that lead to the interruption of normal brain signals.

In children with epilepsy, the disorder can be managed with medication and diet. Several cases of pediatric epilepsy continue into adulthood without seizure. Levetiracetam and oxcarbazepine are two of the most commonly prescribed drugs because their side effect profile is relatively safer compared to other available antiepileptic drugs, said Dr Erin Fedak Romanowski.

Assessment of the link between the drugs and the fracture


Children (representative image)Stocksnap.io

For the study, the authors looked at fracture incidence rates in 561 children and adolescents with epilepsy over a five-year period. They also observed incidence rates of fractures in about 271,000 children who were not epileptic and were not taking anti-epileptic drugs. Children with at least five years of continuous enrollment in a health plan – allowing for a one-year baseline (eg, pre-ASM exposure) and four years of follow-up – were included in the study.

During the course of the study, it was noted that 12.8 percent of the children on oxcarbazepine had suffered a fracture. Compared to this, only 7.5 percent taking levetiracetam suffered a fracture. In children without epilepsy, 8.5 percent had a fracture.

“Knowing that oxcarbazepine is associated with a higher risk of fracture will allow clinicians to be more careful with the children they prescribe the drug. Some children will be at greater risk for a fracture than others initially; this is another factor to take in assessing the complexity of which drugs to use for whom and when, ”said Dr Fedak Romanowski.

Complications of treatments

Human brain

Human brain (representative image)Pixabay

Although the study results call for more research into the effects of epilepsy drugs, Dr Whitney stressed that it does not not mean that oxcarbazepine is not fit for prescription or that all children with epilepsy should be prescribed levetiracetam.

It is known that many children and adolescents with epilepsy also suffer from neurodevelopmental disorders such as cerebral palsy. This particular population is known to be prone to a higher risk of fracture. However, the side effects of levetiracetam can also affect children’s mental health. Mental health problems are one of the most common comorbidities in children with neurodevelopmental disorders.

This is called iatrogenesis or medical problems that arise due to medical care. Although anti-epileptic drugs serve their purpose of preventing seizures, some can cause secondary complications such as bone fragility and behavior or mood problems.


A child with a fractured hand (Representative image)Here

“Our goal for patients is ‘no seizures, no side effects.’ However, there is no perfect anti-seizure drug, and all of them have potential side effects. But doctors can use all of this information. available to take a personalized approach that optimizes patient health outcomes, ”noted Dr. Fedak Romanowski.

Additional research required

Based on the results of the study, the team intends to determine the reason for the link between oxcarbazepine and the increase in fragility fractures during the specific time window. The authors specify that it is only after this research that it will be possible to assess whether it would be beneficial for children to receive complementary therapies treating bone fragility.

“As bone development has distinct periods that establish certain structural aspects, we are interested in studying whether certain drugs alter the biology required to form the structure of bone. If so, perhaps we can develop a treatment. to counteract these effects, so that children can benefit from seizure reduction without weakening the bones, ”concluded Dr. Whitney.

Source link

https://kepplah.com/study-links-commonly-prescribed-antiepileptic-drugs-to-increased-fracture-risk-in-children-with-epilepsy/feed/ 0